Clinical Watch: Definium's LSD for GAD Phase 3 - Efficacy Debates and Dosing Strategy Impact

Definium Therapeutics announced positive primary and key secondary endpoint results from its Phase 3 trial of LSD (DT120) for Generalised Anxiety Disorder (GAD). However, expert analysis raises questions about the relatively low single-dose remission and response rates compared to existing GAD treatments, suggesting that future regulatory approvals for psychedelics might benefit from multi-dose protocols. This insight is crucial for businesses monitoring the medical psychedelics landscape, highlighting potential future dosing requirements and efficacy standards that could influence product development and compliance strategies.

Definium Therapeutics reported positive Phase 3 results for its LSD (DT120) in treating Generalised Anxiety Disorder (GAD). While primary and secondary endpoints were met, neuroscientist Martijn Arns noted that the 14% remission and 43% response rates for a single dose are lower than typical FDA-approved GAD treatments (28-45% remission).

Arns suggests potential "under-dosing" in psychedelic trials, proposing that multiple dosing sessions, similar to trends seen in Compass Pathways' TRD studies, could significantly increase response and remission rates over time.

This discussion highlights an ongoing debate in psychedelic drug development regarding optimal dosing frequency and its impact on long-term efficacy, a key factor for future regulatory success and market adoption.

Sentinel Insight